Henry Friesen

YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Lombard Life Sciences (Lombard Life Sciences) is a venture capital firm founded in 2002. The firm is headquartered in Winnipeg, Canada.

Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada.

Sanofi Pasteur Ltd. develops, manufactures, and markets vaccines and immunotherapeutic products. It offers vaccines for haemophilus influenza type B (Hib), diphtheria, pertussis, poliomyelitis, tetanus, hepatitis A, influenza, poliomyelitis, rabies, meningococcal disease, typhoid fever, and yellow fever, as well as oncology products for bladder cancers. The company was founded John Gerald FitzGerald in 1914 and is headquartered in Toronto, Canada.